Guide your symptomatic SAS patients – including low-risk patients – to the superior* treatment1-3

PARTNER 3 Trial demonstrated unprecendented clinical outcomes.2,4-5
At 1 year, SAPIEN 3 TAVR demonstrated 3X lower risk of death and disabling stroke compared with surgery.2

from death or disabling stroke
at 1 year with SAPIEN 3 TAVR vs 97.1% for surgery (P = 0.03)
Compared to 2.9% death or disabling stroke at 1 year for surgery (P = 0.03)

PARTNER 3 Trial: Primary endpoint

30 Days 1 Year
SAPIEN 3 TAVR
(n = 496)
Surgery
(n = 454)
SAPIEN 3 TAVR
(n = 496)
Surgery
(n = 454)
P-Value
All-Cause Death 0.4% 1.1% 1.0% 2.5% P = 0.09
All Stroke 0.6% 2.4% 1.2% 3.1% P = 0.04
Rehospitalization** 3.4% 6.5% 7.3% 11.0% P = 0.046

All-cause death, stroke, and rehospitalization at 1 year: 8.5% TAVR vs. 15.1% for surgery (P = 0.001)

30 Days
SAPIEN 3 TAVR
(n = 496)
Surgery
(n = 454)
All-Cause Death 0.4% 1.1%
All Stroke 0.6% 2.4%
Rehospitalization** 3.4% 6.5%

All-cause death, stroke, and rehospitalization at 1 year: 8.5% TAVR vs. 15.1% for surgery (P = 0.001)

1 Year
SAPIEN 3 TAVR
(n = 496)
Surgery
(n = 454)
P-Value
All-Cause Death 1.0% 2.5% P = 0.09
All Stroke 1.2% 3.1% P = 0.04
Rehospitalization** 7.3% 11.0% P = 0.046

All-cause death, stroke, and rehospitalization at 1 year: 8.5% TAVR vs. 15.1% for surgery (P = 0.001)

Improved quality of life from baseline

Low rate of permanent pacemaker

* The PARTNER 3 TRIAL, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.
Excludes multiplicity adjustment Leon 2019.
** Rehospitalization (valve-related or procedure-related and including heart failure).

Help your patients understand the benefits of TAVR vs surgical aortic valve replacement

View comparison chart

Watch the Edwards SAPIEN 3 Ultra TAVR transfemoral procedure video

Recommended resources

See all resources

Give your patients the best chance at these outcomes and experiences.

Guide them to a Heart Team  for a TAVR evaluation

References:   1. FDA Letter: SAPIEN approval letter 2011. 2. Mack MJ, Leon MB, Thourani VH. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. 3. Fifteen Years of TAVR; Where Are They Now? American College of Cardiology, July 20, 2017. https://www.acc.org/latest-in-cardiology/articles/2017/07/19/15/42/fifteen-years-of-tavr-where-are-we-now. 4. Leon MB, Mack MJ. PARTNER 3: transcatheter or surgical aortic valve replacement in low risk patients with aortic stenosis. Presented at ACC 2019; March 2019; New Orleans, LA. 5. The Partner 3 Trial Clinical Study Report; April 2019.